Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3852870 | Diálisis y Trasplante | 2011 | 6 Pages |
Abstract
We reviewed the new data published on this drug, as well as the results from the main clinical trials. Lanthanum carbonate shows an adequate safety profile and is highly active in terms of binding dietary phosphorus. Results from comparative trials versus sevelamer show a higher efficacy in terms of reduction of serum phosphate in favor of lanthanum carbonate. Both drugs may slow the progression of vascular calcifications in patients with CKD compared with calcium-based binders. This finding, as well as the potential benefit of lanthanum carbonate in increasing life expectancy in CKD patients over 65 years old, needs to be confirmed in new, long-term comparative trials.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
MarÃa Luisa González Casaús, Emilio González Parra, VÃctor Manuel Navas Serrano, Carolina Gracia Iguacel, Pilar de Ribera Pieras, Jesús Egido de Los RÃos,